NCT05918913 2025-09-05Expanded Access Program for RevumenibSyndax PharmaceuticalsNo longer available1 FDA
NCT04008524 2025-08-06A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological MalignanciesInstitute of Hematology & Blood Diseases Hospital, ChinaAvailable
NCT02437019 2017-03-20Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Janssen-Cilag Farmaceutica Ltda.Approved for marketing
NCT00423826 2016-02-29Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseBarbara Ann Karmanos Cancer InstituteNo longer available